A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review
| Autor: | Li‑Ying Zhang, Yuan Shao, Yu‑Ping Zhang, Lin Wang, Ming‑Wei Shi, Xue‑Ying Cai, Chun‑Wei Xu, Yu‑Wang Tian, Lu‑Ping Wang, Yang Li |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty Lung Neoplasms Oncogene Proteins Fusion DNA Mutational Analysis Bone Neoplasms Adenocarcinoma Biology medicine.disease_cause Biochemistry Translocation Genetic Genetics medicine Humans Anaplastic lymphoma kinase Anaplastic Lymphoma Kinase Genetic Predisposition to Disease Epidermal growth factor receptor Molecular Biology Genetic Association Studies Aged Mutation Receptor Protein-Tyrosine Kinases Cancer Cell cycle medicine.disease Molecular medicine Lymphoma ErbB Receptors Radiography Oncology Cancer research biology.protein Molecular Medicine Female |
| Zdroj: | Molecular Medicine Reports. 12:4370-4375 |
| ISSN: | 1791-3004 1791-2997 |
| DOI: | 10.3892/mmr.2015.4001 |
| Popis: | The echinoderm microtubule associated protein like 4‑anaplastic lymphoma kinase (EML4‑ALK) fusion is almost mutually exclusive to epidermal growth factor receptor (EGFR) or K‑RAS mutation in non‑small cell lung cancer (NSCLC), and it is extremely rare for patients to exhibit both mutations. The present study reported the case of a 71-year‑old female diagnosed with adenocarcinoma, exhibiting mutations in EGFR and EML4‑ALK. The present study treated this patient with EGFR‑TK inhibitors, as the first line therapy, and gefitinib therapy revealed a good response until now. In addition, previously reported cases and associated literature were reviewed. The present study provided a greater understanding of the molecular biology and optimal treatment for patients with NSCLC with >1 driver mutation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|